A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil; OK-432 and Montanide; ISA-51 in patients with cancers expressing NY-ESO-1 antigen
Phase of Trial: Phase I
Latest Information Update: 12 May 2016
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; Montanide ISA-51; Picibanil
- Indications Cancer
- Focus Adverse reactions
- 22 Jul 2014 Status changed from recruiting to completed, as per University Hospital Medical Information Network - Japan.
- 25 Jan 2012 Planned End Date changed from 1 Dec 2010 to 1 Dec 2012 as reported by University Hospital Medical Information Network - Japan.
- 05 Jun 2009 New trial record.